Clinical trials: Medication Absorption
Healthy Participants
A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.
The purpose of this study is to learn how a certain amount of [14C] PF-06821497 is taken up into the bloodstream and removed from the body. The study is seeking participants who are: Males aged 18 years or older.
- Trial name
- NCT06392230
- Testing
- Oral [14C] PF-06821497, Oral PF-06821497, IV [14C] PF-06821497
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants
A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
The purpose of this study is to learn about how much PF-07220060 will be taken up and processed by healthy male participants. The study is seeking for participants who: are males aged 18 to 65 years and are healthy.
- Trial name
- NCT06267963
- Testing
- Oral [14C]PF-07220060, Oral PF-07220060, IV [14C] PF-07220060
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar® in healthy volunteers.
- Trial name
- NCT06797427
- Testing
- DPH001, Nexavar (Sorafenib)
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Disruptive Pharma
Healthy
A Study to Assess the Bioavailability of ASP015K
The objective of the study is to assess the bioavailability of ASP015K within the gastrointestinal tract.
- Trial name
- NCT01430078
- Testing
- ASP015K
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Diabetes, Healthy
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).
- Trial name
- NCT01518166
- Testing
- liraglutide, atorvastatin, lisinopril
- Where
- Sweden
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Male Volunteers
A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men
The purpose of this study is to learn about how much the study medicine PF-07976016 will be taken up and processed by healthy male participants. The total number of weeks of the study is up to approximately 12 weeks.
- Trial name
- NCT07015918
- Testing
- [14C] PF-07976016, PF-07976016
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants
A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants
The purpose of this study is to characterize the safety, tolerability, drug levels and drug effects of BMS-986196 in healthy participants.
- Trial name
- NCT04882150
- Testing
- BMS-986196
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease
A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718
This study will be conducted to evaluate the AZD5718 pharmacokinetic (PK) doses in order to determine exposure in a new dose range and compare with previous results.
- Trial name
- NCT04087187
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study to Learn How the Study Medicine Called [14C]PF-07054894 is Processed by the Body
The purpose of this study is to learn how quickly and to what extent the study medicine (PF-07054894) is absorbed, broken down, and eliminated from the body.
- Trial name
- NCT07009353
- Testing
- PF-07054894
- Where
- Netherlands
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
The objective of this study is to investigate the effect of the interaction of Erythromycin (CYP3A4/5 moderate inhibitor) on the pharmacokinetic of CHF6001 (CYP3A4/5 substrate) in Healthy Volunteers.
- Trial name
- NCT06395610
- Testing
- CHF6001 DPI, Erythromycin
- Where
- Bulgaria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy Volunteers
A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers
This study aims to determine the proportion of study drug dacomitinib or PF-00299804, that is taken up from the digestive tract into the body when given as an oral tablet compared with that taken up by an intravenous dose.
- Trial name
- NCT01796327
- Testing
- dacomitinib oral, dacomitinib intravenous
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participant
A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants
The purpose of this study is to understand bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of the current PF-07220060 tablet formulation and the proposed…
- Trial name
- NCT07130097
- Testing
- PF-07220060
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Osteoporosis
A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women.
- Trial name
- NCT00540878
- Testing
- SB-751689 oral tablets (400 mg)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
- Trial name
- NCT02527421
- Testing
- DFD01 Spray
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Primus Pharmaceuticals
Pain
Evaluation of Vitrase as a Spreading Agent
The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
- Trial name
- NCT00198484
- Testing
- Vitrase
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- Bausch & Lomb Incorporated
Carcinoid Syndrome
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.
- Trial name
- LX1606-104 (NCT01932528)
- Testing
- 500 mg [14C]-LX1606
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Neoplasms
A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.
The purpose of this study is to assess the safety of R306465 (a drug in development for cancer) in patients with advanced cancer on the maximum dose that can be tolerated.
- Trial name
- NCT00677001
- Testing
- R306465
- Volunteers
- 15 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers
Study to determine and compare the absorption of KUC 7483 CL from different regions of the GI tract with the immediate release formulation and to compare the absorption of particulate versus solution formulations from the…
- Trial name
- NCT02259920
- Testing
- KUC 7483 CL, immediate release tablet, KUC 7483 CL, particulate formulation, KUC 7483 CL, solution formulation
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Drug-Drug Interaction (DDI), Intestinal Absorption
A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects
This study will assess the effect of multiple doses of fidaxomicin on the single dose pharmacokinetics of rosuvastatin in healthy male subjects.
- Conditions
- Drug-Drug Interaction (DDI), Intestinal Absorption, Healthy Subjects, Pharmacokinetics of Rosuvastatin
- Trial name
- NCT02083627
- Testing
- rosuvastatin, fidaxomicin
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Subjects, Pharmacokinetics of YM178
A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers
The purpose of this study is to assess the pharmacokinetic interaction of multiple-dose ketoconazole on single-dose YM178 OCAS and the safety and tolerability of YM178 OCAS alone and in combination with ketoconazole in healthy…
- Trial name
- NCT01476800
- Testing
- YM178 OCAS, Ketoconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc